COVID-19 timeline: It s been one year since the first announced case in the United States
Hearst Television
FacebookTwitterEmail
Jan. 20, 2020
Jan. 21, 2020
Jan. 29, 2020
The White House announces the formation of a new task force that will help monitor and contain the spread of the virus, and ensure Americans have accurate and up-to-date health and travel information, it says.
Jan. 30, 2020
The United States reports its first confirmed case of person-to-person transmission of the coronavirus. On the same day, WHO determines that the outbreak constitutes a Public Health Emergency of International Concern (PHEIC).
Jan. 31, 2020
The Trump administration announces it will deny entry to foreign nationals who have traveled in China in the last 14 days.
2281
2 MANDATORY: Makers of Covishield and Covaxin vaccines will have to submit safety and efficacy data of the ongoing trials periodically. PTI
Dr. Jagat Ram & Rakesh Kochhar
Jagat Ram Director, PGI & Rakesh Kochhar Prof, Gastro Dept
THE new year has begun on a positive note with two vaccines against Covid-19 getting emergency use approval from the Subject Expert Committee of the Drugs Controller General of India (DCGI). Covishield (Oxford University-AstraZeneca) is being manufactured by the Pune-based Serum Institute of India (SII), while Covaxin is being made by Hyderabad-based Bharat Biotech. India reached the tally of one crore Covid-19 cases and 1.5 lakh deaths earlier this month, while the total cases across the world have crossed 9 crore in the past 12 months since the pandemic began.
Search jobs 15-Jan-2021
Treatment of first patient cohort completed in Phase 2a extension of retinal disease study
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on progress with the development of its hRPC (human retinal progenitor cell) therapy candidate for retinal diseases.
The hRPC therapeutic candidate is currently undergoing Phase 2a clinical evaluation for the treatment of the inherited blindness-causing disorder retinitis pigmentosa (RP). The study uses a cryopreserved hRPC formulation, enrols subjects with advanced RP with some remaining central vision and, thus far, has been conducted at two clinical sites in the US.
updated: Jan 14 2021, 07:29 ist
One thousand vials of Covaxin, the Covid-19 vaccine developed by Indian pharmaceutical company Bharat Biotech, arrived at the state vaccine store at Anand Rao Circle here on Wednesday. Each vial contains 20 doses.
SpiceJet’s freighter flight SG 7555 took off from Hyderabad at 8.50 am, carrying three boxes weighing 90 kg of Covaxin, and landed in Bengaluru at 10.23 am.
An official in the immunisation wing of the Karnataka Health Department confirmed to
DH that they had received 20,000 doses of the vaccine.
Unlike Covishield, manufactured by the Serum Institute of India, Covaxin has been approved under the ‘clinical trial’ mode. During the first two months of the rollout, Bharat Biotech has to notify drug regulators every fortnight the adverse effects of the vaccine.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of .
Oxford Immunotec Global PLCJanuary 13, 2021 GMT
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce the start of a collaboration with Valneva. The Company will perform T cell testing on participants receiving Valneva’s inactivated whole-virus COVID-19 vaccine candidate (VLA2001) with the research use only T-SPOT
Discovery SARS-CoV-2 test. The VLA2001-201 study is a randomized Phase I/II clinical study designed to evaluate the safety, tolerability and immunogenicity of an inactivated SARS-CoV-2 virus vaccine candidate in healthy subjects, the first study of its kind performed in Europe.